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Hypertension and diabetes are the very common chronic diseases with 
each prevalence of nearly 30% and 10% among South Korean aged over 30 
and this is increased along with aging. These diseases are well-known risk 
factors for severe diseases including cardiovascular disease (CVD) which is a 
leading cause of death globally, so they needed to manage continually. The 
purpose of this study is to evaluate the effect of consultation program on 
medication adherence in hypertension and diabetes patients. 
In an effort to improve hypertension and diabetes care, National Health 
Insurance Service (NHIS) has implemented a consultation program from July 
2013 for 3 months. This study examined the effect of this program between 
before and after conducting intervention using eligibility, medical treatment 
and health examination data from NHIS. To evaluate the actual effect of the 
intervention, this study select controls which have similar characteristics with 
participants using propensity score matching (PSM), and then the change of 
medication possession ratio were analyzed with Difference-in-Differences 
(DID) method, comparing with participants and controls. 
As results of this study, the effect of consultation program on MPR was 
confirmed with statistical significance in hypertension and diabetes 
participants and all types of MPR group. As for IG-MU, the MPR was 2.27% 
increased after intervention in hypertension participants (p=0.0153) and 
7.26% increase in diabetes participants (p=0.0020). As for IG-MO, the MPR 
was 8.04% decreased after intervention in hypertension participants 
(p=0.0013) and 9.73% decreased in diabetes participants (p=0.0122). And the 
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effect of intervention by state of newly diagnosed patients was also found in 
hypertension participants. 
Through this study results, the effect of consultation program change 
subjects’ medication adherence in an appropriate way. Especially, this study 
shows that the consultation program is more effective in patients who are 
newly diagnosed as hypertension than pre-existing hypertension patients. This 
study provides scientific and documented evidences regarding extended 
enforcement of personalized consultation program to improve medication 
adherence. And this study suggests that it needs to implement consultation 
program which is effective and active management service about chronic 
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Hypertension and diabetes are the very common chronic diseases with 
each prevalence of nearly 30% and 10% among South Korean aged over 30 
and this is increased along with aging according to Korea National Health and 
Nutrition Examination Survey 2013 (KNHNES, 2014). This diseases are well-
known risk factors for severe diseases including cardiovascular disease 
(CVD) which is a leading cause of death globally, so they needed to manage 
continually (Hogan et al., 2003, Collins et al., 1990, Balkrishnan et al., 2003). 
According to World Health Organization (WHO), medication adherence 
is defined as “the extent to which a person’s behavior taking medication, 
following a diet, and/or executing lifestyle changes corresponds with agreed 
recommendations from health care provider” (Sabaté, 2003). Also medication 
adherence is very important factor helps in keeping the vital link between the 
treatment and the therapeutic outcomes in medical care (Parthasarathi and 
Nyfort-Hansen, 2004). But among patients with chronic diseases, it is easy to 
get in trouble with medication adherence and approximately 50% of them do 
not take medication as prescribed (Sabaté, 2003, Lee et al., 2006, Magnabosco 
et al., 2015). Because they have to take medications for an entire life once 
they start to take the medications and moreover most patients with 
hypertension and diabetes tend to be asymptomatic(Donnan et al., 2002, 
Dowell et al., 2002). And medication adherence is affected by the patient’s 
perception and attitude toward their diseases (Magnabosco et al., 2015). 
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Medication non-adherence lead to lots of public health problems in 
patients with chronic diseases (Dartnell et al., 1996, Psaty et al., 1990, Lau 
and Nau, 2004, Balkrishnan et al., 2003). Above all, taking medication under-
dose cause emergency room visit, hospitalization and unscheduled hospital 
visits following increased morbidity, exacerbation of diseases and 
development of complications (Brown and Bussell, 2011, Lau and Nau, 2004). 
Moreover it has demanded that patients who take under-dose pay large 
medical expenses (Balkrishnan et al., 2003, Osterberg and Blaschke, 2005). 
Taking or being prescribed excessive medication also lead to socio-economic 
burden (Elliott et al., 2008). In case of this, it is very hard to have an effect to 
prevent complications although it spends medical expenses and medicine cost 
and it makes using national health insurance ineffective consequentially. 
Previous studies have shown that the various kinds of interventions by 
healthcare provider to improve medication adherence were effective in both 
medication adherence and patient outcomes like their blood pressure or blood 
glucose level (Morgado et al., 2011, Chabot et al., 2003, Bright et al., 2012, 
Elliott et al., 2008). And in 2003 report on medication adherence of WHO, it 
reported that “increasing the effectiveness of adherence interventions may 
have a far greater impact on the health of the population than any 
improvement in specific medical treatments”(Sabaté, 2003). Through these, 
the intervention to improve medication adherence is very important to manage 
chronic diseases in public health aspects. Meanwhile, in an effort to improve 
hypertension and diabetes care, National Health Insurance Service (NHIS) in 
South Korea has implemented an intervention by providing chance to 
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participate the consultation program for medication non-adherence measured 
by medication possession ratio (MPR) in each person who has hypertension or 
diabetes from 2013. But it is hard to evaluate the accurate consultation 
program by comparing the MPR of participants before and after intervention 
so, it is necessary to fix a control group to evaluate the actual impacts 
excluded the natural effect by time passes. Moreover this program provides 
personalized healthcare consultation according to each person’s MPR, so it is 
possible to evaluate the effect of intervention by standards of MPR and to find 
the vulnerable group. This will encourage to shape this program more 






The main purpose of this study is to evaluate the effect of the 
consultation program to improve medication adherence in hypertension and 
diabetes patients. 
Thus, the specific objectives of the study are 
Objective 1: Evaluate the effect of the consultation program on medication 
adherence of patients who are diagnosed with hypertension and diabetes. 
Objective 2: Evaluate the effect of the consultation program on medication 
adherence of patients who are diagnosed with hypertension and diabetes by 
subgroups (age group, gender and state of newly diagnosed patient). 
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2.1 Overview of the intervention 
 
2.1.1 Consultation program to improve medication 
adherence 
 
The consultation program in improve medication adherence by NHIS 
started from 2013 to select appropriate patients according to some criteria in 8 
districts which are within the jurisdiction of 6 branch offices of the NHIS 
during 2012 before providing intervention. The number of participant district 
group combined 2 districts into 1 branch is 2 on account of low population to 
cover. The intervention started from July 2013 for 3 months. 
This intervention was conducted by administrative staffs in NHIS and 
pharmacists in each district. At first, the intervention was fully implemented 
in all eligible patients sending a leaflet. It contains some information about 
this consultation program including the objective of this intervention and 
personalized information about each person’s disease, how to manage their 
disease, the reason why they have to take drugs, their state of medication 
adherence and the importance of medication administration. And also it 
includes contents of further telephone contacts from NHIS to provide 
specialized consultation after one week from receiving a leaflet. The second 
and the third intervention were performed through telephone consultation with 
standardized questionnaire including 13 to 15 questions about medication 
administration and lifestyle behavior. The second intervention placed 
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emphasis on checking participant’s medication-taking behavior and lifestyle 
behavior like smoking, drinking and physical activity state, giving advice and 
correcting inappropriate behavior to right way. Meanwhile, the main purpose 
of third intervention is to check how they change their inappropriate behavior 
to appropriate and also giving advice about effective self-management ways 
of their disease. 
 
 
2.1.2 Measurement of medication adherence 
 
There are several methods to measure medication adherence. But there is 
no ‘gold standard’ measure for it and this makes assessment of adherence 
difficult(Hughes, 2004). In this consultation program, medication adherence 
was calculated by using medication possession ratio (MPR) which is 
commonly used measurement method and the best available measurement of 
medication adherence using administrative data(Halpern et al., 2006, Andrade 
et al., 2006). This is the ratio of total days of medication supplied to total days 
in a period of time(Halpern et al., 2006). MPR was calculated every 6months 
as the first half year and the second half year in this study. For example, if a 
patient with hypertension was prescribed and supplied with hypertension 
medication for 120 days of the first half year, then the MPR was calculated as 
66.3% ((120 days/181 days)*100). When calculating MPR, this study 
considered the subject’s behavioral differences in medical service utilization 
and types of medications by ingredient to resolve overlapped period between 
prescriptions. If a patient was prescribed medication at same hospital and 
same ingredient in each prescription, the overlapped periods were additionally 
 
 7 
added to total prescribed days. But in the cases of each prescription were from 
different hospitals or changed ingredients of medications, overlapped periods 
of prior prescriptions were excluded in total prescribed days.  
 
On the basis of the previous studies, adherence to medication was 
defined as an 80%≤MPR(Cramer et al., 2008, Karve et al., 2009, Lee et al., 
1996, Mallion et al., 1998), but higher MPR has occurred another problems 
related to increased medical health costs. So this study defined 
80%≤MPR<130% as medication adherence. All study subjects who were non-
adherent to mediations were divided into 2 groups according to MPR for the 
second half year of 2012. The first group is intervention group with under 
administration of medicine (IG-UAM) with MPR <80% and the second group 
is the intervention group with over administration of medicine (IG-OAM) 












2.1.3 Literature review about study method for eval
uating the effect of consultation program 
 
The experimental study with randomization is the most proper method to 
evaluate the outcome of system or policy(Ravallion, 2003). But it is 
impossible to select the utilization of the system or policy in random. In 
addition to that, there are an intervention group exposed to the consultation 
program, no control group was assigned when the intervention was conducted. 
To deal with this shortcoming, it is appropriate to use propensity score 
matching (PSM) with difference-in-differences (DID) as quasi-experimental 




2.1.3.1 Propensity score matching (PSM) 
 
PSM is one of effective and artificial method to find an appropriate 
control group when there are only case group(Wang et al., 2009). This method 
constructs control group using matching algorithms to find a similar subjects 
to the case group as possible along a set of covariates(Khandker et al., 2010) 
for reducing selection bias(Dehejia and Wahba, 2002, Austin, 2007, Wang et 
al., 2009). There are two conditions were satisfied before we employ PSM. 
Those are conditional independence assumption and the range of common 
support assumption. After these assumptions were fulfilled, the propensity 
score was estimated to construct control group which has similar 
characteristics with case group. And then controls were matched to each case 
on propensity score. Final step is verifying the covariates are balanced across 
case and control groups in the matched. 
 
2.1.3.2 Difference in Differences (DID) and Difference in Di
fference in Differences (DDD) 
 
DID is the method of analysis comparing the differences between before 
and after conducting system in participant group which was affected by 
system with differences between before and after conducting system in 
control group which was not affected by system for estimating the actual 
effect of system. There need to be satisfied pre-condition before this method 
was employed. It is parallel trend assumption says that if there are no 
implementation of system, the aspect of transition in accordance with time is 
same in between participant and control groups. 
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The equation for the DID is shown below; 
 
t represent the period, especially t=0 is a period of before conducting 
intervention while t=1 is a period of after conducting intervention. I =1 is 
participant group and I =0 represent control group. YP and YC are measured 
values of intervention participant group and control group respectively. In 
other words, change of outcome variable in accordance with consultation 
program is the amount of difference between the period of before and after 
intervention in control group subtracted from difference between periods in 
participant group. But it is hard to consider time varying covariates so using 
regression-based DID can estimate the effects adjusting it 
DDD used same principle with DID but this added one more division 
criteria to evaluate the effect by new division. In other words, this is the 
method to estimate the differences between the differences in accordance with 
implementing intervention in participant and control groups within groups 
after that, estimate the differences between groups. This statistical method 
eliminates remaining endogenous relationship in covariates. 
But only using DID or DDD has some weakness of selection bias and 
endogeneity occurred from unobserved heterogeneity. So, there needs to find 
a solutions to deal with this matter, PSM is the way to overcome this 




Chapter 3. Methods 
 
 
3.1 Data source 
 
This study used secondary data which consisted of eligibility 
database(included age, gender, residence, 10 brackets of insurance fee and so 
on), medical treatment database(included diagnosis code which are classified 
according to International Classification of Disease 10th Revision(ICD-10), 
data about prescriptions like drug name, dosage, visit date, duration of stay in 
hospital and so on) and health examination database (included height, weight, 
blood pressure, results of blood test and so on) of NHIS in South Korea (Song 
et al., 2014) from 2009 to 2014. Total duration of this study is from January 
2009 to December 2014 including the intervention period was from July 2013 
to September 2013.  
South Korea has a national health insurance system which cover all 
South Korean, so the NHIS database contains all information for all South 
Korean who use medical services(Shin et al., 2013). And all people over 40 
years old are provided a health examination for every 2 years(Song et al., 
2014). Therefore, NHID (National Health Insurance Data) is not limited to 
specific geographical areas, hospitals or patients(Shin et al., 2013, Song et al., 
2014). 
NHIS provide data without the individual identifier. Thus resident 
registration number as identifier number codes of all study subject were 
changed into anonymous numeric codes representing each individual to 
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protect private patient information(Shin et al., 2013). The exemption of ethics 
approval for this study has been obtained from Institutional Review Board of 
Seoul National University under E1510/002-007. 
 
3.2 Strategy for the selection of study sample 
 
In the case of participants in consultation program to improve medication 
adherence, there are several criteria when NHIS selected suitable patients who 
have hypertension or diabetes for this intervention program in 8 districts 
which are within the jurisdiction of 6 branch offices of the NHIS at 2012. The 
criteria are like below.  
1. The patients who have medical records with diagnosed by 
hypertension (International Classification of Disease, 10th revision 
code (ICD-10 code): I10, I11, I12, I13, I15) and diabetes (ICD-
10code: E10, E11) for the first half year of 2012. 
2. The patients who have prescription records of medication which is 
classified hypertension and diabetes for the first half year of 2012. 
3. The patients who have more than two times of medical service use 
which are combined medical record and prescription record for more 
than 14 days or have only one time of medical service use with more 
than 30 days of prescribed medication for the first half year of 2012.  
4. The patients who don’t have rare diseases like cancer, chronic renal 
failure, dementia, and so on. 
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5. The patient who are aged above 45 and below 80. 
This study considered variables about lifestyle behaviors (state of 
drinking, smoking and physical activity) as covariates. So subjects who took 
health examination provided by NHIS before and after consultation program 
are included. According to these criteria, the total number of participants 
sample in this study is 10,990(Figure 2.). 
 
Figure 2. Diagram for selection of participant sample 
 
In order to evaluate the effects of the intervention on the participation of 
the consultation program, one needs to compare the outcomes between 
intervention participants and comparable non-participants(Sari and Osman, 
2015). But there is only participants group exposed to the intervention, no 
control group was assigned when the intervention was conducted by NHIS. 
There needed to define and select the optimal non-participant group as control 
so, the same criteria were applied when extract that group. 
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Before we applied these criteria, control districts which have similar 
character to the intervention conducted districts were selected by 22 indicators 
for the purpose of having a homogeneity between control districts and case 
districts in district level for reducing selection bias. That indicators are made 
up 15 health state indicators and 7 socio-economic state (SES) indicators and 
the all values are represented state of each district in 2012. The used 
indicators are recorded in appendix 1 and 2. Using these indicators, Z-score of 
all districts in South Korea were calculated for standardizing. At first, Z-score 
of each district and indicator were calculated. Formally the Zij is defined as; 
                                               (1) 
where subscript i stands for 22 health state and SES indicators and j stands for 
254 districts respectively.  is the raw value of some district and some 
indicator,  is the mean of the indicator and  is the standard deviation of 
the indicator. Using calculated all standardized scores of each district and 
indicator, final Z-score of each district, , defined as below; 
                                        (2) 
where subscript j stands for 254 districts like above equation. And then 2 
control districts to 1 intervention district were selected among total districts in 
accordance with calculated Z-score which have similar score with each 
intervention district (Control districts 1). 
Meanwhile, South Korea is divided into 8 provinces (e.g., Gyeonggi-do), 
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1 special autonomous province (Jeju-do), 6 metropolitan cities (e.g., Busan), 1 
metropolitan autonomous city (Sejong) and 1 special city (Seoul). Each 
division has their own characteristics, so (1) and (2) were done within each 
division. As a result, additional 2 control districts to 1 intervention district 
were selected (Control districts 2) so, total 4 control districts to 1 intervention 




Table 1. Intervention districts and selected control districts with Z-score. 
Intervention district name Z-score* 
Control districts 1 
Z-score* 
Control districts 2 
Districts name Z-score Districts name Z-score 




Daegu A 0.0410 
0.0581 
Seoul A1 0.0560 
Ulsan A 0.0539 Seoul A2 0.0911 




Gyeonggi-do B -0.2048 
-0.1818 
Gyeonggi-do B1 -0.1986 
Seoul B -0.1780 Gyeonggi-do B2 -0.1779 




Gyeonggi-do C -0.6846 
-0.4779 
Chungcheongbuk-do C1 -0.3301 
Gangwon-do C 0.8495 Chungcheongbuk-do C2 -0.2469 




Chungcheongbuk-do D -0.1591 
-0.0962 
Jeollabuk-do D1 -0.1439 




Gyeongsangbuk-do E -0.1059 
-0.1460 
Jeollabuk-do E1 -0.1907 











Districts name Z-score Districts name Z-score 




Gyeonggi-do F -0.0545 
-0.1572 
Gyeongsangbuk-do F1 -0.1617 




Chungcheongnam-do G 0.0074 
0.1259 
Gyeongsangbuk-do G1 0.0635 
Gyeongsangbuk-do G 0.0269 Gyeongsangbuk-do G2 0.1320 




Seoul H1 0.3373 
0.0510 
Gyeongsangnam-do H1 0.0329 
Seoul H2 0.3498 Gyeongsangnam-do H2 0.0828 
*: Z-score for intervention districts in accordance with calculating method. 
 
 18 
After control districts were selected, control sample is extracted by same 
criteria with participants. Figure 3 shows the description of process used to 
identify study control sample. The total number of final control sample is 
made of non-participants of consultation program is 176,883. 
Finally, this study distinguished patients who are newly diagnosed as a 
hypertension or diabetes patient. It is reasonable to separate new patients from 
pre-existing patient by the reason of new patients’ unfamiliarity with 
managing chronic disease. So it is more easy to be a medication non-adherent 
for new patients than pre-existing patients. Moreover it is important to study 
about the effect of consultation program on new patients because if the new 
patients recognized the importance about taking medicine as a result from this 
consultation program, they will be good at managing their health by 
themselves for a long time. And this prevent further complications and 
unnecessary medical service use and health cost. The new patients is 
operationally defined as patients who don’t have any medical records with 
diagnosed hypertension and diabetes in 2011 and patients who don’t have any 




Figure 3. Diagram for selection of control sample 
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3.3 Analysis strategies 
 
In this study, all eligibility, medical treatment and health examination 
data of both participant group and control group was extracted from whole 
NHIS database to examine the effect of this consultation program. After 
pooling data by each person, this study used quasi-experimental design with 
PSM, DID and DDD as an analysis method to improve the effect of 
consultation program.  
At first, participants and controls which are used in this study with 
almost same characters excluding the state of participation are selected using 
1:1 PSM method. This study did chi-square test as a test of homogeneity 
between participant and control group after PSM. A p-value ≤ 0.05 was 
considered statistically significant. After constructing the participant and 
control group using PSM, regression-based DID approach was used to 
estimate the effects of this program adjusting some factors affect the study 
outcome. And then, this study analyzed the effect of consultation program 
using DDD method to distinguish the systemic differences of effects on the 
outcomes (Figure 4). 
All statistical analyzes were performed using the SAS enterprise guide 











3.3.1 Study variables 
 
3.3.1.1 Variables for PSM 
 
Using PSM, control group which has very similar character with 
participants is selected to investigate the actual effect of consultation program. 
There are so many factors affect the relationship between the consultation 
program and the study outcome. It is impossible to control all factors, but 
there are many studies to investigate the affecting factors to medication 
adherence. So this study uses key variables from previous studies. These 
factors can divide into 2 parts, one of them is demographic and socio-
economic part and the other is clinical part. The former contains age, gender, 
residence area, 5 brackets of insurance fee and so on while the latter contains 
the state of new patient, body mass index (BMI), blood pressure, blood 
glucose and so on. Additionally, this study contains variables about lifestyle 
behavior (state of drinking, smoking and physical activity). The detailed 




















Table 2. The definition of variables used in PSM. 
Variables Values of variables 
Age group 
1: 45-59 





1: Seoul A and control districts 
(District 1) 
2: Gyeonggi-do B and control districts 
(District 2) 
3: Chungcheongbuk-do C and control 
districts 
(District 3) 
4: Jeollabuk-do D, E and control districts 
(District 4) 
5: Gyeongsangbuk-do F, G and control 
districts 
(District 5) 
6: Gyeongsangnam-do H and control districts 
(District 6) 





0: Pre-existing patients 









3: Grade 1 hypertension 
4: Grade 2 hypertension 
5: Grade 3 hypertension 
Blood glucose level 
1: Normal 





Variables Values of variables 
Blood glucose level 
1: Normal 





3: Hypertension and Diabetes 
MPR groups in hypertension 
1: Under-dose 
2: Over-dose 














BMI, blood pressure and blood glucose level are provided as values in 
accordance with health examination. These variables are changed into 
categorical variable in order to using PSM. BMI is divided into 4 groups as 
underweight, normal, overweight, obese according to WHO BMI 
classification (WHO, 2004). Blood pressure is divided into 5 groups as 
normal, pre-hypertension (pre-HTN), grade 1 hypertension (G1 HTN), grade 
2 hypertension (G2 HTN), grade 3 hypertension (G3 HTN) (WHO and Group, 
2003). Finally, blood glucose level is divided into 3 groups as normal 
impaired fasting glucose (IFG), diabetes (Mellitus, 2005). The details of 
classification standards are records in appendix 3. 
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3.3.1.2 Variables for DID and DDD 
 
Variables used in DID and DDD are presented in Table 3. With regard to 
evaluate the effect on medication adherence, the dependent variable is MPR 
representing medication adherence. It was calculated by types of diseases 
(hypertension and diabetes) and types of MPR groups (IG-MU and IG-MO). 
And MPR was calculated in every 6 months from July 2011 to December 
2014. The period defined as before intervention is from July 2011 to June 
2013 and the period defined as after intervention is from July 2013 to 
December 2014. Meanwhile, calculated MPR in every 6 months included 
carryover medications from last half year.  
The independent variables are state of participation and period of before 
and after intervention. Age group, gender and state of new patient are used in 
DDD model to investigate the effect by these subgroups. The interaction term 
for state of participation and period of before and after intervention is 
estimated in DID model. In the case of DDD model, the interaction term for 
state of participation, period of before and after intervention and subgroup is 
estimated.  
The control variables contain residence area, state of disabled, 5 brackets 
of insurance fee, value of BMI, blood pressure, value of blood glucose, state 




Table 3. The definition of variables used in DID and DDD. 
Variables Values of variables 
Dependent 
variable 





Participants group Participants =1 












45-59 = 1 
Over 60 = 2 
Gender* 
Male = 1 
Female = 2 
State of new patient* 
Pre-existing  
patient = 0 
Newly diagnosed 





Variables Values of variables 
Control 
variable 
Residence area District 1 to District 6 
State of disabled 
Non-disabled = 0 
Disabled =1 
5 brackets of insurance fee 
0 to 5 
(0: Medical aid 
beneficiaries) 
BMI Continuous variable 
Systolic blood pressure Continuous variable 
Diastolic blood pressure Continuous variable 
Blood glucose Continuous variable 
State of drinking 
No = 0 
Yes =1 
State of smoking 
No = 0 
Yes =1 
State of physical activity 
No = 0 
Yes =1 




3.3.2 Application of the model 
 
The purpose of this study is to evaluate the effect of consultation 
program to improve medication adherence using DID and DDD with PSM. 
This intervention was implemented to specific subjects for specific period, so 
the effect is investigated by estimating the interaction term of state of 
participation and period. And the effects by subgroups are investigated by 
estimating the interaction term of state of participation, period and subgroups. 
The model of this study is as follows: 
1. Analysis Ⅰ: the effect on medication adherence 
- Model Ⅰ: DID model 
 
i: subject, t: year, Y: MPR by disease group and MPR group 
 
2. Analysis Ⅱ: the effect on medication adherence by subgroups 
- Model Ⅱ: DDD model 
 
 
i: subject, t: year, Y: MPR by disease group and MPR group 
Subgroups: gender, age group and state of newly diagnosed patients 
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Chapter 4. Results 
 
 
4.1 Descriptive statistics of the study variables 
 
This study used logit model with participation of consultation program as 
a binary variable to estimate propensity score. The control group was selected 
by 1:1 Nearest Matching algorithm which is one of the PSM method. 
Participants are matched to controls on 8 digits of the propensity score 
Before PSM, study subjects consisted of 10,990 of participants and 
176,883 of controls. After selected controls having similar propensity score 
with participants, whole study subjects consist of 8,646 of participants and 
control group respectively. Figure 5 shows the distribution of propensity score 
in participant and control group 
 




Table 4 shows the distribution about demographic and socio-economic 
characters of study subjects before and after PSM and also shows the results 
of homogeneity test.  
First of all, about the results of homogeneity test before PSM, there are 
heterogeneity between participant group and control group about all covariate 
except two variables; disease (p-value: 0.6694) and physical activity (p-value: 
0.0687). But after PSM, there are no differences between participant group 
and control group in all covariates. It means that the characters of two groups 
are very similar in all observable covariates except the state of participation in 
consultation program.  
With regard to the distribution of age group, gender, residence area, 
disabled and 5 brackets of insurance fee as a demographic and socio-
economic characters, the distribution of all variables are same in participant 
group and control group. As for age group, 48.29% of participants and 
controls are in age group 45-59 years of age on the baseline period and 
51.71% of both two groups are in age group over 60. Among study subjects, 
there are more male subjects than female subjects with the proportion of 
53.38% as male and 46.62% as female. About the distribution of residence 
area, more than 70% of study subjects live in District 1 (26.07%), District 2 
(21.72%) and District 3 (25.32%). 7.01% of participants and controls are 
disabled. Finally, there are more subjects who were charged higher national 
health insurance fee than subjects who are included in lower brackets of all in 
both participants and control groups. 
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Table 5 shows the distribution about clinical characters of study subjects 
before and after PSM and also shows homogeneity between participant group 
and control group. 
As for clinical characters, the distribution of participant and control 
groups is same except 2 variables; blood pressure and drinking. 11.83% of 
participants and controls are newly diagnosed patients at 2012. With regard to 
the results of BMI, 55.82% of study subjects are in the range of underweight 
with the highest proportion of each participant and control groups. The 
second-highest proportion of study subjects is overweight with 40.08%. As for 
blood pressure, distribution of participant and control groups are little 
different but approximately half of the study subjects are in the range of pre-
hypertension state. Among the study subjects who are diagnosed hypertension 
as results of blood pressure examination, the case of G1 HTN took the largest 
proportion of the others with 22% of participant group and 22.3% of control 
group. Approximately 49% of participants and controls are in normal range of 
blood glucose level, while, 17.5% of participants and 17.05% of controls are 
diagnosed diabetes as results of blood test. There are 78.09% of both two 
groups have HTN and 11.22% have diabetes. And the subjects who have both 
HTN and diabetes take 10.69%. Among participants and controls who have 
HTN, 83.01% are included IG-MU and 16.99% are in IG-MO. And about 
subjects who have diabetes, 68.32% are in IG-MU while, 31.58% are in IG-
MO. There are more subjects who are non-drinking (participant group: 
76.87%, control group: 77.24%), non-smoking (participant group: 84.48%, 
control group: 84.48%) and who don’t physical activity (participant group: 
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Table 4. Comparison the homogeneity of demographic and socio-economic characters between participant and control group in initial 
study sample dataset and matched study sample dataset. 
Variables 
Initial study sample Matched study sample 
Participant group Control group 
p-value 
Participant group Control group 
p-value 
N (%) N (%) N (%) N (%) 
Total number of 
study sample 
10990 (100) 176883 (100) 
 
8646 (100) 8646 (100) 
 
Age group 
45-59 5608 (51.03) 74791 (42.28) 
<.0001* 
4175 (48.29) 4175 (48.29) 
1.0000 
over 60 5382 (48.97) 102092 (57.72) 4471 (51.71) 4471 (51.71) 
Gender 
Male 6047 (55.02) 89454 (50.57) 
<.0001* 
4615 (53.38) 4615 (53.38) 
1.0000 
Female 4943 (44.98) 87429 (49.43) 4031 (46.62) 4031 (46.62) 
Residence 
area 
District 1 2868 (26.1) 36497 (20.63) 
<.0001* 
2254 (26.07) 2254 (26.07) 
1.0000 
District 2 2594 (23.6) 25878 (14.63) 1878 (21.72) 1878 (21.72) 
District 3 680 (6.19) 13326 (7.53) 498 (5.76) 498 (5.76) 
District 4 1032 (9.39) 33488 (18.93) 858 (9.92) 858 (9.92) 
District 5 1243 (11.31) 22322 (12.62) 969 (11.21) 969 (11.21) 






Initial study sample Matched study sample 
Participant group Control group 
p-value 
Participant group Control group 
p-value 




9997 (90.96) 157758 (89.19) 
<.0001* 
8040 (92.99) 8040 (92.99) 
1.0000 
Disabled 993 (9.04) 19125 (10.81) 606 (7.01) 606 (7.01) 
5 brackets of 
insurance fee 
0 84 (0.77) 3339 (1.89) 
<.0001* 
44 (0.51) 44 (0.51) 
1.0000 
1 2102 (19.19) 30363 (17.22) 1584 (18.32) 1584 (18.32) 
2 1741 (15.89) 25501 (14.46) 1317 (15.23) 1317 (15.23) 
3 1810 (16.52) 27347 (15.51) 1399 (16.18) 1399 (16.18) 
4 2171 (19.82) 35561 (20.17) 1761 (20.37) 1761 (20.37) 





Table 5. Comparison the homogeneity of clinical characters and lifestyle behavior state between participant and control group in 
initial study sample dataset and matched study sample dataset. 
Variables 
Initial study sample Matched study sample 
Participant group Control group 
p-value 
Participant group Control group 
p-value 
N (%) N (%) N (%) N (%) 
Newly 
diagnosed 
No 9109 (82.88) 170091 (96.16) 
<.0001* 
7623 (88.17) 7623 (88.17) 
1.0000 
Yes 1881 (17.12) 6792 (3.84) 1023 (11.83) 1023 (11.83) 
BMI 
Underweight 5972 (54.34) 89576 (50.64) 
<.0001* 
4826 (55.82) 4826 (55.82) 
1.0000 
Normal 146 (1.33) 1719 (0.97) 34 (0.39) 34 (0.39) 
Overweight 4323 (39.34) 74842 (42.31) 3465 (40.08) 3465 (40.08) 
Obese 549 (5.00) 10746 (6.08) 321 (3.71) 321 (3.71) 
Blood 
Pressure 
Normal 2139 (19.46) 31529 (17.82) 
<.0001* 
1686 (19.50) 1638 (18.95) 
0.2385 
Pre-HTN 5496 (50.01) 92489 (52.29) 4354 (50.36) 4436 (51.31) 
G1 HTN 2419 (22.01) 41091 (23.23) 1902 (22.00) 1928 (22.30) 
G2 HTN 748 (6.81) 9920 (5.61) 568 (6.57) 504 (5.83) 
G3 HTN 188 (1.71) 1854 (1.05) 136 (1.57) 140 (1.62) 
Blood 
glucose level 
Normal 5091 (46.32) 80533 (45.53) 
0.0005* 
4214 (48.74) 4227 (48.89) 
0.7245 IFG 3679 (33.48) 62292 (35.22) 2919 (33.76) 2945 (34.06) 





Initial study sample Matched study sample 
Participant group Control group 
p-value 
Participant group Control group 
p-value 
N (%) N (%) N (%) N (%) 
Disease 
HTN 8035 (73.11) 129811 (73.39) 
0.6694 
6752 (78.09) 6752 (78.09) 
1.0000 DM 1364 (12.41) 22008 (12.44) 970 (11.22) 970 (11.22) 
HTN & DM 1591 (14.48) 25064 (14.17) 924 (10.69) 924 (10.69) 
MPR groups in 
hypertension 
IG-MU 8295 (86.17) 11775 (7.60) 
<.0001* 
6372 (83.01) 6372 (83.01) 
1.0000 
IG-MO 1331 (13.83) 143100 (92.40) 1304 (16.99) 1304 (16.99) 
MPR groups in 
diabetes 
IG-MU 2335 (79.02) 2943 (6.25) 
<.0001* 
1294 (68.32) 1294 (68.32) 
1.0000 
IG-MO 620 (20.98) 44129 (93.75) 600 (31.68) 600 (31.68) 
Drinking 
No 8316 (75.67) 137244 (77.59) 
<.0001* 
6646 (76.87) 6678 (77.24) 
0.5628 
Yes 2674 (24.33) 39639 (22.41) 2000 (23.13) 1968 (22.76) 
Smoking 
No 8976 (81.67) 150870 (85.29) 
<.0001* 
7304 (84.48) 7304 (84.48) 
1.0000 
Yes 2014 (18.33) 26013 (14.71) 1342 (15.52) 1342 (15.52) 
Physical activity 
No 7252 (65.99) 115212 (65.13) 
0.0687 
5738 (66.37) 5769 (66.72) 
0.6173 





4.2 Evaluation of effect on medication adherence of th
e consultation program 
 
4.2.1 Evaluation of effect in hypertension patients 
 
Table 6 shows the results of DID analysis about the effect on medication 
adherence in hypertension patients by types of MPR groups. 
As for subjects who are in IG-MU, MPR of participants decreased of 
10.46% from 64.49% to 54.02% while, MPR of controls decreased of 12.74% 
from 78.54% to 65.80%. The value of DID is 2.27% with the statistical 
significance (p=0.0153). It means that the consultation program improved 
MPR of participants who have hypertension with taking their medication 
under-dose.  
Among subjects who are in IG-MO, MPR of participants decreased of 
3.15% from 128.42% to 125.27% while, MPR of controls is 4.89% increased 
from 114.09% to 118.98%. The value of DID is -8.04% with the statistical 
significance (p=0.0013). Therefore the consultation program is effective 
intervention in reducing MPR of participants who have hypertension with 















Participant group 64.49 54.02 -10.46  
Control group 78.54 65.80 -12.74  
Difference between groups  -14.06  (<.0001)* -11.78  (<.0001)* 
  
DID 




Participant group 128.42 125.27 -3.15 
Control group 114.09 118.98 4.89 
Difference between groups  14.33 (<.0001)* 6.29 (0.0009)* 
  






Table 7 represents the results of DDD about the effect on medication 
adherence in hypertension subjects who take hypertension medication with 
under-dose by subdivisions (gender, age group and state of newly diagnosed 
patients). The effects of consultation program by subdivisions are not 
statistically significant in all divisions. 
As for gender, MPR of female participants is 2.61% increased after 
participate in consultation program according to the results of DID in female 
group (p=0.0478). But in the case of male group, MPR of male participants is 
2.61% increased but the effect is not statistically significant. And also value of 
DDD is not statistically significant. Through this, it can be concluded that 
gender doesn’t affect the effect of consultation program systemically in this 
study. But the intervention is more effective in female group than male group. 
As for age group, MPR of participants who are in age group with 45-59 
years of age is 0.97% increased than control group as a result of DID while, 
MPR of participants who are in age group with over 60 years of age is 3.66% 
increased with statistical significance. So this intervention is more effective in 
older age group than younger age group. But the value of DDD is not 
statistically significant. Therefore, age group also doesn’t affect the effect of 
consultation program. 
As for the change of MPR by states of newly diagnosed patients, MPR of 
newly diagnosed participants are 6.21% increased than control group 
(p=0.0177). And the MPR of pre-existing participant increase of 1.83% but 
this is not statistically significant. And also value of DDD is not statistically 
significant. Through this, it can be concluded that state of newly diagnosed 
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patients doesn’t affect the effect of consultation program systemically but, this 















Participant group 67.22 62.63 -4.59 
Control group 80.05 73.50 -6.56 
Difference between groups  -12.84 (<.0001)* -10.87 (<.0001)* 
  
DID         1.97 (0.1409) 
Female 
(N=6,436) 
Participant group 60.94 56.48 -4.46 
Control group 76.21 69.13 -7.07 
Difference between groups  -15.27 (<.0001)* -12.66 (<.0001)* 
  
DID         2.61 (0.0478)* 




















Participant group 57.1641 54.2674 -2.90 
Control group 68.5246 64.6606 -3.86 
Difference between groups  -11.36 (<.0001)* -10.39 (<.0001)* 
  
DID         0.97 (0.5044) 
over 60 
(N=6,782) 
Participant group 71.12 65.61 -5.50 
Control group 87.48 78.31 -9.17 
Difference between groups  -16.36 (<.0001)* -12.70 (<.0001)* 
  
DID         3.67 (0.0031)* 






Participant group 35.92 49.85 13.93 
Control group 59.38 67.10 7.72 
Difference between groups  -23.47 (<.0001)* -17.25 (<.0001)* 
  




Participant group 81.87 74.70 -7.18 
Control group 94.64 85.64 -9.00 
Difference between groups  -12.77 (<.0001)* -10.95 (<.0001)* 
  
DID         1.83 (0.0693) 
DDD = 4.39 (0.1179)   
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Table 8 represents the results of DDD about the effect on medication 
adherence in hypertension subjects who take hypertension medication with 
over-dose by subdivisions (gender, age group and state of newly diagnosed 
patients). The effects of consultation program by subdivisions are not 
statistically significant in all divisions. 
With regard to gender, MPR of male participants decreased of 10.22% 
after intervention (p=0.00212). MPR of female participants decreased of 
4.38% but it is not statistically significant. MPR of male participants are 
higher than female participants in both before and after intervention. And the 
value of DDD is not statistically significant. According to these results, this 
consultation program reduced their MPR more in male group than female 
group but state of gender doesn’t affect the effect of consultation program. 
As for age group, MPR decreased of 10.56% in age group with 45-59 
years of age (p=0.0079) while, MPR decreased of 9.09% in age group with 
over 60 years of age. These results represent that this intervention is more 
effective in younger age group.  
As for state of newly diagnosed patients, MPR decrease of 18.06% in 
participants who are newly diagnosed patients as a result of DID in this 
subgroup. But this is not statistically significant. Meanwhile, MPR of 
participants who are pre-existing patients decreased of 7.73% with statistical 















Participant group 136.80 122.59 -14.21 
Control group 118.19 114.20 -3.99 
Difference between groups  18.61 (<.0001)* 8.39 (0.0005)* 
  
DID         -10.22 (0.0012)* 
Female 
(N=962) 
Participant group 118.24  105.60  -12.64 
Control group 111.11  102.85  -8.26 
Difference between groups  7.13 (0.0082)* 2.75 (0.3769) 
  
DID         -4.38 (0.2888) 





















Participant group 108.64 96.58 -12.06 
Control group 106.80 105.30 -1.50 
Difference between groups  1.84 (0.4563) -8.72 (0.0052)* 
  
DID         -10.56 (0.0079)* 
over 60 
(N=1,444) 
Participant group 146.29 130.29 -16.00 
Control group 122.10 115.19 -6.91 
Difference between groups  24.19 (<.0001)* 15.10 (<.0001)* 
  
DID 
    
-9.09 (0.0049)* 






Participant group 119.88 116.47 -3.41 
Control group 80.72 95.37 14.65 
Difference between groups  39.16 (<.0001)* 21.10 (0.0241)* 
  




Participant group 141.78 127.69 -14.09 
Control group 128.38 122.02 -6.36 
Difference between groups  13.40 (<.0001)* 5.67 (0.0035)* 
  
DID         -7.73 (0.0025)* 




4.2.2 Evaluation of effect in diabetes patients 
 
Table 9 shows the results of DID analysis about the effect on medication 
adherence in diabetes patient by types of MPR groups. 
With regard to subjects who are in IG-MU, MPR of participants 
decreased of 5% from 71.10% to 66.10% while, MPR of controls decreased of 
12.26% from 85.93% to 73.66%. The value of DID is 7.26% with the 
statistical significance (p=0.0020). Therefore, the consultation program is 
effective in increasing MPR of participants who have diabetes with taking 
under-dose medication. 
Meanwhile, in the case of subjects who are in IG-MO, MPR of 
participants is 2.7% decreased from 135.52% to 132.82% while, MPR of 
controls increased of 7.03% from 125.97% to 133%. So, the value of DID is -
9.73% (p=0.0122). Therefore, consultation program reduce MPR of 















Participant group 71.10 66.10 -5.00 
Control group 85.93 73.66 -12.26 
Difference between groups  -14.83 (<.0001)* -7.57 (<.0001)* 
  
DID         7.26 (0.0020)* 
IG-MO 
(N=1,200) 
Participant group 135.52 132.82 -2.7 
Control group 125.97 133 7.03 
Difference between groups  9.55 (0.0002)* -0.18 (0.9531) 
  









Table 10 represents the results of DDD about the effect on medication 
adherence in diabetes subjects who take diabetes medication with under-dose 
by subdivisions (gender, age group and state of newly diagnosed patients). 
The effects of consultation program by subdivisions are not statistically 
significant in all divisions. 
As for gender, MPR is increased of 7.83% in male participant group than 
male control group after intervention with statistical significance (p=0.0093) 
while, MPR is increased of 6.51% in female participant group with statistical 
non significance. And it is possible to conclude that the effect of consultation 
program as per gender doesn’t exist in this study according to the result of 
DDD.  
As for age group, MPR increase of 8.36% in participant who are in age 
group of 45-59 after intervention while, MPR is 6.33% increase in participant 
who are in age group of over 60. The amount of change is larger in younger 
age group than older age group. But the estimated value of DDD is not 
statistically significant so, there is no differences in effect of consultation 
program as per age group. 
Finally, in the case of state of newly diagnosed patients, MPR is 
increased of 8.64% in participants who are newly diagnosed after intervention. 
And MPR of participants who are pre-existing patients is 7.30% increased 
with statistical significance (p=0.0031). But there are no differences in effect 
of consultation program as per state of newly diagnosed patients with non- 















Participant group 69.40 73.27 3.87 
Control group 83.16 79.19 -3.97 
Difference between groups  -13.76 (<.0001)* -5.92 (0.0093)* 
  
DID         7.83 (0.0093)* 
Female 
(N=990) 
Participant group 69.44 68.53 -0.91 
Control group 86.04 78.62 -7.42 
Difference between groups  -16.60 (<.0001)* -10.09 (0.0004)* 
  
DID         6.51 (0.0865) 




















Participant group 56.76 63.63 6.87 
Control group 71.77 70.28 -1.49 
Difference between groups  -15.01 (<.0001)* -6.66 (0.0130)* 
  
DID         8.36 (0.0152)* 
over 60 
(N=1,244) 
Participant group 82.50 80.16 -2.34 
Control group 97.17 88.50 -8.67 
Difference between groups  -14.67 (<.0001)* -8.33 (0.0005)* 
  
DID         6.33 (0.0519) 






Participant group 38.30 56.53 18.23 
Control group 63.04 72.63 9.59 
Difference between groups  -24.74 (<.0001)* -16.10 (0.0061)* 
  




Participant group 89.47 89.98 0.51 
Control group 103.46 96.67 -6.79 
Difference between groups  -13.99 (<.0001)* -6.69 (0.0004)* 
  
DID         7.30 (0.0031)* 
DDD = 1.34 (0.8722)   
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Table 11 represents the results of DDD about the effect on medication 
adherence in diabetes subjects who take diabetes medication with over-dose 
by subdivisions (gender, age group and state of newly diagnosed patients). 
The effects of consultation program by subdivisions are not statistically 
significant in all divisions. 
As for gender, MPR of male participants is 8.84% decrease compared 
with controls after intervention while, MPR of female participants is 11.64% 
decreased. But these estimated values of DID by gender are not statistically 
significant. Also the estimated value of DDD is not statistically significant.  
In the case of age group, MPR of older age group decreased of 12.05% 
compared with controls after intervention with statistical significance 
(p=0.0176). But the effect of consultation program on MPR in younger age 
group is no statistically significant.  
And as for state of newly diagnosed patients, MPR decreased of 42.20% 
in participants who are newly diagnosed after intervention. And MPR of 
participants who are pre-existing patients is 9.06% decreased with statistical 
significance (p=0.0216). But there are no differences in effect of consultation 



















Participant group 145.15 132.39 -12.76 
Control group 130.83 126.91 -3.92 
Difference between groups  14.32 (<.0001)* 5.48 (0.1336) 
  
DID         -8.84 (0.0658) 
Female 
(N=408) 
Participant group 126.04 113.41 -12.63 
Control group 125.32 124.33 -0.99 
Difference between groups  0.72 (0.8699) -10.92 (0.0303)* 
  
DID         -11.64 (0.0805) 




















Participant group 117.35 107.94 -9.41 
Control group 118.10 118.59 0.49 
Difference between groups  -0.75 (0.8437) -10.65 (0.0274)* 
  
DID         -9.90 (0.1059) 
over 60 
(N=646) 
Participant group 155.47 139.22 -16.25 
Control group 137.26 133.06 -4.20 
Difference between groups  18.21 (<.0001)* 6.16 (0.0991)* 
  
DID         -12.05 (0.0176)* 






Participant group 95.55 90.68 -4.87 
Control group 115.26 152.59 37.33 
Difference between groups  -19.71 (0.2395) -61.91 (0.0012)* 
  




Participant group 154.95 142.04 -12.91 
Control group 144.60 140.75 -3.85 
Difference between groups  10.35 (<.0001)* 1.29 (0.6651) 
  
DID         -9.06 (0.0216)* 
DDD = -33.13 (0.1983)   
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4.3 Evaluation of effect on medication adherence of th
e consultation program in specific group. 
 
Figure 6 shows the trend of MPR by disease and types of intervention 
from the second half year of 2011(2011_2) to the second half year of 
2014(2014_2). Participants and controls are divided into IG-MU and IG-MO 
in accordance with calculated MPR in the second half year of 2012. 
According to figure 6, it is possible to predict there are some participants who 
have large difference between MPR of the second half year of 2012 and the 
first half year of 2013 as a period of before intervention. So, this study 
extracted participants who are in same MPR group due to calculate MPR in 
both the second half year of 2012 and the first half year of 2013 among 
participants who are selected by PSM. And then, controls who are matched 
that participants with propensity score were extracted. Figure 7 shows the 
MPR trend with newly extracted study subjects. MPR trends of participants in 
hypertension and diabetes have more consistency than before. 
DID and DDD analysis were done with newly extracted study subjects 
and the results are represented in Table 12. Other results are represented in 
Appendix 4-9. The results of DID are same with previous analysis. The MPRs 
of participants who are in hypertension and diabetes IG-MU are decreased 
due to the consultation program, while the MPRs of participants who are in 
IG-MO are decreased. On the other hands, there are no effects by subgroups 
in previous analysis, but there are some effects by state of newly diagnosed 
patients with newly extracted study subjects. 
As for hypertension subjects who are in IG-MU, MPR is 13.81% 
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increase in participants group with newly diagnosed patients then control 
group (p <.0001). And MPR in participants group with pre-existing patient 
increase of 3.35%, but this is not statistically significant. The effect of 
consultation program is not clarified in the pre-existing hypertension patients 
but according to estimate value of DDD, the effect of consultation program 
can be changed by state of newly diagnosed patients. Therefore, MPR of 
newly diagnosed participants increase of 10.46% then MPR of pre-existing 
participants in IG-MU (p=0.0058). Like this, as for hypertension subjects who 
are in IG- MO, MPR of newly diagnosed participant decrease of 62.81% then 

























Participant group 23.24 45.64 22.40 
Control group 57.58 66.18 8.59 
Difference between groups  -34.34 (<.0001)* -20.53 (0.0093)* 
  
DID         13.81 (<.0001)* 
Pre- 
Existing 
Participant group 59.25 55.47 -3.78 
Control group 91.63 84.50 -7.13 
Difference between groups  -32.39 (<.0001)* -29.03 (<.0001)* 
  
DID         3.35 (0.0708) 





Participant group 195.62 148.63 -46.99 
Control group 66.03 98.59 32.57 
Difference between groups  129.59 (<.0001)* 50.04 (0.0229)* 
  
DID         -79.56 (0.0062)* 
Pre- 
Existing 
Participant group 203.05 179.63 -23.42 
Control group 128.75 122.08 -6.67 
Difference between groups  74.30 (<.0001)* 57.55 (0.0005)* 
  
DID         -16.75 (0.0010)* 














Participant group 28.19 53.48 25.28 
Control group 74.15 80.47 6.32 
Difference between groups  -45.95 (<.0001)* -27.00 (0.0061)* 
  
DID         18.96 (0.1026) 
Pre- 
Existing 
Participant group 71.76 78.04 6.27 
Control group 101.05 98.77 -2.28 
Difference between groups  -29.29 (<.0001)* -20.74 (0.0004)* 
  
DID         8.55 (0.0781)* 





Participant group 236.15 241.65 5.50 
Control group 24.29 78.43 54.13 
Difference between groups  211.86 (0.0011)* 163.22 (0.1205) 
  
DID         -48.63 (0.6940) 
Pre- 
Existing 
Participant group 215.76 191.27 -24.49 
Control group 143.70 138.66 -5.04 
Difference between groups  72.06 (<.0001)* 52.61 (0.0004)* 
  
DID         -19.45 (0.0077)* 






Chapter 5. Discussion and Conclusion 
 
 
These days, many people have chronic diseases like hypertension and 
diabetes which are very common chronic diseases globally. So, it is very 
important to manage chronic diseases for healthy life. Because of this diseases 
tend to be asymptomatic unless complications arise(Donnan et al., 2002), it is 
easy to get in trouble with managing their chronic disease appropriately. 
Taking medication is widely known as one of factors which affect 
administration of disease directly(Parthasarathi and Nyfort-Hansen, 2004). 
And patients who have chronic disease have to take medication for an entire 
life after diagnosed so, it is important to manage medication adherence.  
NHIS implemented consultation program to improve medication 
adherence with 3 times interventions for 3 months in 2013. Among People 
who have hypertension and diabetes are defines using medical and 
prescription record in NHIS database, the consultation program provided 
intervention for only people who are medication non-adherent. Moreover, this 
program is on the way to expand the range of districts where this intervention 
enforced year after year. So, it is necessary to evaluate how this consultation 
program achieved its goals and who is affected by this in a positive way. 
Therefore, the purpose of this study is to evaluate the effect of consultation 




As results of this study, the effect of consultation program on MPR was 
confirmed with statistical significance in hypertension and diabetes 
participants and all types of MPR group. As for IG-MU, the MPR was 2.27% 
increased after intervention in hypertension participants (p=0.0153) and 
7.26% increase in diabetes participants (p=0.0020). As for IG-MO, the MPR 
was 8.04% decreased after intervention in hypertension participants 
(p=0.0013) and 9.73% decreased in diabetes participants (p=0.0122). But the 
results of analysis about the effect of consultation program by subgroups were 
not statistically significant. There are some medication non-adherent 
participants whose MPR of the second half year of 2012 is different from 
MPR of the first half year of 2013. These participants are eliminated for the 
purpose of evaluating more accurate effect of consultation program. After that, 
the effect of intervention by state of newly diagnosed patients was found in 
hypertension participants. The MPR of participants who are newly diagnosed 
as hypertension in 2012 was increase of 10.46% than MPR of participants 
who are pre-existing patient in IG-MU (p=0.0058). And the MPR of 
participants who are newly diagnosed as hypertension in 2012 was 62.81% 
decrease than the MPR of participants who are pre-existing patient in IG-MO 
(p=0.0332).  
The above results are come from each participant’s medication-taking 
behavior. Medication adherence is one of health care habit so, it is not easy to 
change in a short time. But as for the newly diagnosed patients, the habit of 
taking medication doesn’t fully develop. However, as for the pre-existing 
patients who are medication non-adherent, they may make a habit about 
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taking medication inappropriate way for a long-time, so the amount of 
difference in MPR may be lower than newly diagnosed patient. Moreover, the 
intervention program consisted of 1 time of providing leaflet and 2 times of 
telephone consultation for 3 months. This is not sufficient to correct their 
medication adherence even though the effect in pre-existing patient group was 
confirmed. And the barriers to good medication-taking behavior clearly tend 
to occur early in the therapeutic course (Burnier, 2006). So, it is important to 
provide consultation program to newly diagnosed patients. And if this 
consultation program focuses on newly diagnosed patients, it will be one of 
the way to improve effectiveness of this intervention than to provide 
consultation program to pre-existing patient. As for pre-existing patient, this 
consultation program is too short to improve their medication adherence, so it 
needs to develop a long-term consultation program. 
This study has strengths in some parts. First, this study use z-score 
matching with 22 indicators about health state and socio-economic state in 
district level and propensity score matching with various covariates. Therefore 
this study investigated using study sample which was reduced or eliminated 
possible selection bias. So, the effect measured in this study represents the 
actual effect of this program. Second, this study use MPR as a measurement 
method of medication adherence considered the subject’s behavioral 
differences in medical service utilization and types of medications by 
ingredient to resolve overlapped period between prescriptions. Third, this 
study has subgroups so it is possible to find which subgroup took more 
benefits to correct their medication adherence in a good and healthy way. 
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Some limitations of this study deserve a mention. First, the study have 
short period of after intervention. In the case of behavior, it has been made for 
a long time, so it is hard to change their habit in a short period. And previous 
study reported that the initial effect started to decrease after the intervention 
period (Otsuki et al., 2009). However, this consultation program has 
conducted since 2013, so this study only can investigate short-term effect of 
the consultation program. Therefore further study will be needed to long-term 
effect of this consultation program on medication adherence. Second, the 
consultation providers of this program consisted of administrative staffs in 
NHIS and pharmacists in each district so, there are some differences in effect 
of intervention by provider. But the information about it wasn’t obvious. So 
there need to record some information about consultants. 
Finally, the effect of consultation program on MPR was confirmed in 
hypertension and diabetes participants who have problem in medication 
adherence. According to the results, this study provides a scientific and 
documented evidence regarding extended enforcement of personalized 
consultation program to improve medication adherence. And this study 
suggest that it needs to implement consultation program which is effective 






ANDRADE, S. E., KAHLER, K. H., FRECH, F. & CHAN, K. A. 2006. Meth
ods for evaluation of medication adherence and persistence using auto
mated databases. Pharmacoepidemiology and drug safety, 15, 565-574. 
AUSTIN, P. C. 2007. Propensity-score matching in the cardiovascular surgery l
iterature from 2004 to 2006: a systematic review and suggestions for i
mprovement. The Journal of Thoracic and Cardiovascular Surgery, 134,
 1128-1135. e3. 
BALKRISHNAN, R., RAJAGOPALAN, R., CAMACHO, F. T., HUSTON, S. 
A., MURRAY, F. T. & ANDERSON, R. T. 2003. Predictors of medica
tion adherence and associated health care costs in an older population 
with type 2 diabetes mellitus: a longitudinal cohort study. Clinical ther
apeutics, 25, 2958-2971. 
BRIGHT, D. R., KROUSTOS, K. R., THOMPSON, R. E., SWANSON, S. C., 
TERRELL, S. L. & DIPIETRO, N. A. 2012. Preliminary results from 
a multidisciplinary university-based disease state management program f
ocused on hypertension, hyperlipidemia, and diabetes. Journal of pharm
acy practice, 25, 130-135. 
BROWN, M. T. & BUSSELL, J. K. Medication adherence: WHO cares?  May
o Clinic Proceedings, 2011. Elsevier, 304-314. 
BURNIER, M. 2006. Medication Adherence and Persistence as the Cornerstone
 of Effective Antihypertensive Therapy*. American journal of hypertens
ion, 19, 1190-1196. 
CHABOT, I., MOISAN, J., GR GOIRE, J.-P. & MILOT, A. 2003. Pharmacist 
intervention program for control of hypertension. Annals of Pharmacoth
erapy, 37, 1186-1193. 
COLLINS, R., PETO, R., MACMAHON, S., GODWIN, J., QIZILBASH, N., 
HEBERT, P., EBERLEIN, K., TAYLOR, J., HENNEKENS, C. & FIEB
ACH, N. 1990. Blood pressure, stroke, and coronary heart disease: par
t 2, short-term reductions in blood pressure: overview of randomised d
rug trials in their epidemiological context. The Lancet, 335, 827-838. 
CRAMER, J., BENEDICT, A., MUSZBEK, N., KESKINASLAN, A. & KHAN,
 Z. 2008. The significance of compliance and persistence in the treatm
ent of diabetes, hypertension and dyslipidaemia: a review. International
 journal of clinical practice, 62, 76-87. 
DARTNELL, J., ANDERSON, R. P., CHOHAN, V., GALBRAITH, K. J., LYO
N, M., NESTOR, P. J. & MOULDS, R. 1996. Hospitalisation for adve
rse events related to drug therapy: incidence, avoidability and costs. Th
e Medical Journal of Australia, 164, 659-662. 
DEHEJIA, R. H. & WAHBA, S. 2002. Propensity score-matching methods for 
nonexperimental causal studies. Review of Economics and statistics, 84,
 151-161. 
DONNAN, P., MACDONALD, T. & MORRIS, A. 2002. Adherence to prescrib
ed oral hypoglycaemic medication in a population of patients with Typ
e 2 diabetes: a retrospective cohort study. Diabetic Medicine, 19, 279-
284. 
DOWELL, J., JONES, A. & SNADDEN, D. 2002. Exploring medication use t
o seek concordance with'non-adherent'patients: a qualitative study. Britis
h Journal of General Practice, 52, 24-32. 
ELLIOTT, R. A., BARBER, N., CLIFFORD, S., HORNE, R. & HARTLEY, E.
 
 64 
 2008. The cost effectiveness of a telephone-based pharmacy advisory 
service to improve adherence to newly prescribed medicines. Pharmacy
 World & Science, 30, 17-23. 
HALPERN, M. T., KHAN, Z. M., SCHMIER, J. K., BURNIER, M., CARO, J.
 J., CRAMER, J., DALEY, W. L., GURWITZ, J. & HOLLENBERG, 
N. K. 2006. Recommendations for evaluating compliance and persisten
ce with hypertension therapy using retrospective data. Hypertension, 47,
 1039-1048. 
HOGAN, P., DALL, T. & NIKOLOV, P. 2003. Economic costs of diabetes in 
the US in 2002. Diabetes Care, 26, 917-32. 
HUGHES, C. M. 2004. Medication non-adherence in the elderly. Drugs & agin
g, 21, 793-811. 
KARVE, S., CLEVES, M. A., HELM, M., HUDSON, T. J., WEST, D. S. & 
MARTIN, B. C. 2009. Good and poor adherence: optimal cut-point for
 adherence measures using administrative claims data. Current medical 
research and opinion, 25, 2303-2310. 
KHANDKER, S. R., KOOLWAL, G. B. & SAMAD, H. A. 2010. Handbook o
n impact evaluation: quantitative methods and practices, World Bank P
ublications. 
KNHNES 2014. Statistics of health behavior and chronic disease 2013. 
LAU, D. T. & NAU, D. P. 2004. Oral antihyperglycemic medication nonadhere
nce and subsequent hospitalization among individuals with type 2 diab
etes. Diabetes Care, 27, 2149-2153. 
LEE, J. K., GRACE, K. A. & TAYLOR, A. J. 2006. Effect of a pharmacy ca
re program on medication adherence and persistence, blood pressure, a
nd low-density lipoprotein cholesterol: a randomized controlled trial. Ja
ma, 296, 2563-2571. 
LEE, J. Y., KUSEK, J. W., GREENE, P. G., BERNHARD, S., NORRIS, K., S
MITH, D., WILKENING, B. & WRIGHT, J. T. 1996. Assessing medic
ation adherence by pill count and electronic monitoring in the African
 American Study of Kidney Disease and Hypertension (AASK) Pilot S
tudy. American journal of hypertension, 9, 719-725. 
MAGNABOSCO, P., TERAOKA, E. C., OLIVEIRA, E. M. D., FELIPE, E. A.,
 FREITAS, D. & MARCHI-ALVES, L. M. 2015. Comparative analysis
 of non-adherence to medication treatment for systemic arterial hyperte
nsion in urban and rural populations. Revista latino-americana de enfer
magem, 23, 20-27. 
MALLION, J.-M., BAGUET, J.-P., SICHE, J.-P., TREMEL, F. & DE GAUDE
MARIS, R. 1998. Compliance, electronic monitoring and antihypertensi
ve drugs. Journal of hypertension. Supplement: official journal of the I
nternational Society of Hypertension, 16, S75-9. 
MELLITUS, D. 2005. Diagnosis and classification of diabetes mellitus. Diabete
s care, 28, S37. 
MORGADO, M., ROLO, S. & CASTELO-BRANCO, M. 2011. Pharmacist inte
rvention program to enhance hypertension control: a randomised contro
lled trial. International journal of clinical pharmacy, 33, 132-140. 
OSTERBERG, L. & BLASCHKE, T. 2005. Adherence to medication. New Eng
land Journal of Medicine, 353, 487-497. 
OTSUKI, M., EAKIN, M. N., RAND, C. S., BUTZ, A. M., ZUCKERMAN, I.
 H., OGBORN, J., BILDERBACK, A. & RIEKERT, K. A. 2009. Adh
erence feedback to improve asthma outcomes among inner-city childre
n: a randomized trial. Pediatrics, 124, 1513-1521. 
PARTHASARATHI, G. & NYFORT-HANSEN, K. 2004. A Text Book of Clinic
 
 65 
al Pharmacy Practice: Essential Concepts and Skills, Orient Blackswan. 
PSATY, B. M., KOEPSELL, T. D., WAGNER, E. H., LOGERFO, J. P. & IN
UI, T. S. 1990. The relative risk of incident coronary heart disease ass
ociated with recently stopping the use of β-blockers. Jama, 263, 1653-
1657. 
RAVALLION, M. 2003. Assessing the poverty impact of an assigned program. 
The impact of economic policies on poverty and income distribution: e
valuation techniques and tools, 1. 
SABAT , E. 2003. Adherence to long-term therapies: evidence for action, Worl
d Health Organization. 
SARI, N. & OSMAN, M. 2015. The effects of patient education programs on 
medication use among asthma and COPD patients: a propensity score 
matching with a difference-in-difference regression approach. BMC heal
th services research, 15, 332. 
SHIN, S., SONG, H., OH, S.-K., CHOI, K. E., KIM, H. & JANG, S. 2013. E
ffect of antihypertensive medication adherence on hospitalization for ca
rdiovascular disease and mortality in hypertensive patients. Hypertensio
n Research, 36, 1000-1005. 
SONG, S. O., JUNG, C. H., SONG, Y. D., PARK, C.-Y., KWON, H.-S., CHA,
 B. S., PARK, J.-Y., LEE, K.-U., KO, K. S. & LEE, B.-W. 2014. Bac
kground and data configuration process of a nationwide population-base
d study using the korean national health insurance system. Diabetes &
 metabolism journal, 38, 395-403. 
WANG, H., YIP, W., ZHANG, L. & HSIAO, W. C. 2009. The impact of rural
 mutual health care on health status: evaluation of a social experiment
 in rural China. Health Economics, 18, S65-S82. 
WHO & GROUP, I. S. O. H. W. 2003. 2003 World Health Organization (WH
O)/International Society of Hypertension (ISH) statement on manageme
nt of hypertension. Journal of hypertension, 21, 1983-1992. 
WHO, E. C. 2004. Appropriate body-mass index for Asian populations and its






Appendix 1. Health state indicators used calculating Z-score 
health state indicators 
1 Prevalence of diagnosed hypertension in over 30 years old 
2 Prevalence of diagnosed diabetes in over 30 years old 
3 Averaged BMI 
4 Walking rate 
5 Vigorous physical activity rate 
6 High-risk drinking rate 
7 Hypertension medication treatment rate in over 30 years old 
8 Hypertension treatment rate in over 30 years old 
9 Diabetes treatment rate in over 30 years old 
10 Self-reported hypertension control rate 
11 Self-reported diabetes control rate 
12 Yearly drinking rate 
13 Drinking rate 
14 Smoking rate 
15 Health institute use rate 
 
 
Appendix 2. Socio-economic state indicators used calculating Z-score 
Socio-economic state (SES) indicators 
1 Mortality rate 
2 Averaged amount of local tax collection 
3 Gross regional domestic product (GRDP) per capita 
4 Activity rate 
5 Accession rate 
6 Unemployment rate 













Normal SBP:<120mmHg and DBP:<80mmHg 
Pre-HTN SBP: 120-139mmHg or DBP: 80-89mmHg 
G1 HTN SBP: 140-159mmHg or DBP: 100-109mmHg 
G2 HTN SBP: 160-179mmHg or DBP: 100-109mmHg 
G3 HTN SBP: ≥180mmHg or DBP: ≥110mmHg 
Blood glucose level  
Normal <100mg/dl 
IFG 100-125mg/dl 













Participant group 43.57 43.38 -0.19 
Control group 76.38 70.32 -6.05 
Difference between groups  -32.81 (<.0001)* -26.95 (<.0001)* 
  
DID 
    
5.86 (0.0003) 
IG-MO 
Participant group 187.31 167.65 -19.66 
Control group 111.41 110.30 -1.11 
Difference between groups  75.90 (<.0001)* 57.35 (<.0001)* 
  
DID 




















Participant group 49.43 51.59 2.15 
Control group 79.81 76.48 -3.34 
Difference between groups  -30.38 (<.0001)* -24.89 (<.0001)* 
  
DID 
    
5.49 (0.0194)* 
Female 
Participant group 38.80 41.60 2.79 
Control group 73.81 70.34 -3.47 
Difference between groups  -35.01 (<.0001)* -28.74 (<.0001)* 
  
DID 
    
6.26 (0.0052)* 




Participant group 38.59 44.52 5.93 
Control group 67.46 66.38 -1.08 
Difference between groups  -28.87 (<.0001)* -21.86 (<.0001)* 
  
DID 
    
7.01 (0.0041)* 
Over 60 
Participant group 49.69 49.85 0.16 
Control group 86.10 80.41 -5.69 
Difference between groups  -36.41 (<.0001)* -30.56 (<.0001)* 
  
DID 
    
5.85 (0.0071)* 
DDD = 1.1583 (0.7232)   
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Participant group 194.23 171.14 -23.09 
Control group 114.42 110.05 -4.37 
Difference between groups  79.81 (<.0001)* 61.09 (<.0001)* 
  
DID 
    
-18.72 (0.0018)* 
Female 
Participant group 180.30 153.88 -26.42 
Control group 113.17 105.08 -8.09 
Difference between groups  67.13 (<.0001)* 48.80 (<.0001)* 
  
DID 
    
-18.33 (0.0432)* 




Participant group 171.28 164.58 -6.70 
Control group 105.02 106.35 1.33 
Difference between groups  66.26 (<.0001)* 58.23 (<.0001)* 
  
DID 
    
-8.03 (0.4894) 
Over 60 
Participant group 199.03 170.76 -28.27 
Control group 120.39 113.50 -6.89 
Difference between groups  78.64 (<.0001)* 57.26 (<.0001)* 
  
DID 
    
-21.38 (0.0001)* 
DDD = 13.3352 (0.3009)   
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Participant group 54.76 59.75 4.99 
Control group 86.27 81.21 -5.06 
Difference between groups  -31.51  (<.0001)* -21.46  (<.0001)* 
  
DID 
    
10.05 (0.0245)* 
IG-MO 
Participant group 208.67 189.27 -19.40 
Control group 135.87 135.87 0.00 
Difference between groups  72.80 (<.0001)* 53.40 (<.0001)* 
 















Participant group 58.98 72.06 13.08 
Control group 93.83 93.83 -0.01 
Difference between groups  -34.86 (<.0001)* -21.77 (<.0001)* 
  
DID 
    
13.09 (0.0196)* 
Female 
Participant group 54.25 56.16 1.91 
Control group 80.06 77.40 -2.66 
Difference between groups  -25.81 (<.0001)* -21.24 (0.0002)* 
  
DID 
    
4.57 (0.5395) 




Participant group 37.02 53.75 16.73 
Control group 75.87 80.30 4.43 
Difference between groups  -38.85 (<.0001)* -26.55 (<.0001)* 
  
DID 
    
12.30 (0.0458)* 
Over 60 
Participant group 76.52 75.93 -0.58 
Control group 98.73 92.68 -6.05 
Difference between groups  -22.21 (<.0001)* -16.74 (0.0005)* 
  
DID 
    
5.47 (0.4020) 
DDD = 6.83 (0.4464)   
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Participant group 210.24 187.84 -22.4 
Control group 129.22 125.00 -4.22 
Difference between groups  81.02 (<.0001)* 62.84 (<.0001)* 
  
DID 
    
-18.18 (0.0367)* 
Female 
Participant group 191.48 163.09 -28.39 
Control group 137.01 132.01 -5.00 
Difference between groups  54.47 (<.0001)* 31.08 (0.0021)* 
  
DID 
    
-23.39 (0.0785) 




Participant group 185.29 178.05 -7.24 
Control group 120.91 120.18 -0.73 
Difference between groups  64.38 (<.0001)* 57.87 (<.0001)* 
  
DID 
    
-6.51 (0.6577) 
Over 60 
Participant group 217.19 186.94 -30.25 
Control group 141.05 135.30 -5.75 
Difference between groups  76.14 (<.0001)* 51.64 (<.0001)* 
  
DID 
    
-24.50 (0.0037)* 














고혈압과 당뇨는 널리 알려진 주요 만성질환으로 30세 이상에서 
그 유병률이 각각 30%, 10%인 것으로 나타났으며 연령이 
증가할수록 유병률이 증가하는 것으로 나타났다. 또한 이는 심각한 
질환의 원인이 되므로 지속적인 관리가 요구된다. 본 연구의 목적은 
투약순응도 향상을 위한 상담 프로그램이 고혈압 및 당뇨 환자에 
있어 투약순응도 변화에 미친 영향을 평가하는 것이다.  
2013년 7월부터 3개월에 걸쳐 시행된 국민건강보험공단의 
적정투약관리 프로그램을 대상으로 건강보험 및 건강 검진 자료를 
활용하여 프로그램 시행 전후로 프로그램의 효과를 분석하였다. 
실제 프로그램의 효과를 평가하기 위해 성향점수매칭법(PSM)을 
활용하여 프로그램 참여자와 유사한 성향을 가진 대조군을 
선정하였고, 에 대하여 각각 이중차이분석(DID)을 실시하였다. 
 분석 결과, 고혈압과 당뇨 환자의 MPR에 따른 과소투약군(IG-
MU)과 과다투약군(IG-MO) 모두에 있어 프로그램의 시행이 
통계적으로 유의한 효과를 가지고 있음을 확인했다. 과소투약군의 
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경우 MPR이 프로그램 시행 후 증가하는 것을 알 수 있었으며 
(고혈압: 2.27% 증가(p=0.0153), 당뇨: 7.26% 증가(p=0.0020)), 
과다투약군의 경우 MPR이 프로그램 시행 후 감소하는 것으로 
확인되었다 (고혈압: 8.04% 감소(p=0.0013), 당뇨: 9.73% 
감소(p=0.0122)). 또한 세부 그룹에 따른 상담프로그램의 효과의 
경우, 성별과 연령에 따른 프로그램의 효과 차이는 유의한 결과값을 
갖지 못하였으나 신규환자 여부에 따른 프로그램의 효과 차이는 
고혈압 대상자들에 있어 신규환자에서의 효과가 기존환자에서의 
효과보다 더 큰 것으로 나타났다 (과소투약군: 10.46% 
(p=0.0058), 과다투약군: -62.81% (p=0.0332)).  
본 연구의 결과를 바탕으로 투약순응도 향상을 위한 상담 
프로그램의 효과를 확인하였으며, 신규환자에게 있어 프로그램이 더 
효과적임을 알 수 있었다. 따라서 본 연구는 개인 수준의 맞춤형 
상담 프로그램의 확대실시의 근거로 활용될 것으로 기대하며, 
효과적이고 적극적인 만성질환 관리 서비스 제공의 필요성을 
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